CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
27.75
1.02%
Market Trading Hours* (UTC) Opens on Monday at 09:10

Mon: 09:10 - 00:00

Tue - Thu: 00:00 - 01:00 09:10 - 00:00

Fri: 00:00 - 01:00 09:10 - 22:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.11
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Pfizer Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 27.49
Open* 27.47
1-Year Change* -35.17%
Day's Range* 27.47 - 28.03
52 wk Range 25.76-45.43
Average Volume (10 days) 38.91M
Average Volume (3 months) 845.89M
Market Cap 158.61B
P/E Ratio 15.43
Shares Outstanding 5.65B
Revenue 68.54B
EPS 1.82
Dividend (Yield %) 5.98078
Beta 0.61
Next Earnings Date Jan 30, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 23, 2024 27.75 0.28 1.02% 27.47 28.03 27.47
Feb 22, 2024 27.47 -0.08 -0.29% 27.55 27.68 27.13
Feb 21, 2024 27.55 0.02 0.07% 27.53 27.64 27.30
Feb 20, 2024 27.45 -0.16 -0.58% 27.61 28.08 27.45
Feb 16, 2024 27.50 0.13 0.47% 27.37 27.83 27.16
Feb 15, 2024 27.37 0.35 1.30% 27.02 27.75 26.97
Feb 14, 2024 27.00 0.09 0.33% 26.91 27.11 26.86
Feb 13, 2024 26.92 -0.69 -2.50% 27.61 27.77 26.81
Feb 12, 2024 27.56 0.11 0.40% 27.45 27.96 27.44
Feb 9, 2024 27.47 0.02 0.07% 27.45 27.59 27.33
Feb 8, 2024 27.45 0.00 0.00% 27.45 27.63 27.36
Feb 7, 2024 27.48 0.04 0.15% 27.44 27.59 27.24
Feb 6, 2024 27.36 0.83 3.13% 26.53 27.67 26.51
Feb 5, 2024 26.53 -0.33 -1.23% 26.86 26.93 26.47
Feb 2, 2024 26.82 -0.31 -1.14% 27.13 27.29 26.64
Feb 1, 2024 27.13 0.08 0.30% 27.05 27.27 26.68
Jan 31, 2024 27.05 0.10 0.37% 26.95 27.46 26.73
Jan 30, 2024 26.93 -0.62 -2.25% 27.55 28.31 26.90
Jan 29, 2024 27.48 0.08 0.29% 27.40 27.57 27.26
Jan 26, 2024 27.38 -0.06 -0.22% 27.44 27.85 27.30

Pfizer Inc Events

Time (UTC) Country Event
Friday, April 26, 2024

Time (UTC)

13:00

Country

US

Event

Pfizer Inc Annual Shareholders Meeting
Pfizer Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Tuesday, April 30, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Pfizer Inc Earnings Release
Q1 2024 Pfizer Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 100330 81288 41651 41172 40825
Revenue 100330 81288 41651 41172 40825
Cost of Revenue, Total 34591 30688 8405 8043 8872
Gross Profit 65739 50600 33246 33129 31953
Total Operating Expense 63779 57636 33839 28841 36763
Selling/General/Admin. Expenses, Total 14305 12256 11402 12485 12419
Research & Development 12381 11582 9340 7731 7713
Depreciation / Amortization 3609 3700 3348 4462 4736
Unusual Expense (Income) 1077 3897 2619 -2914 4675
Other Operating Expenses, Total -2184 -4487 -1275 -966 -1652
Operating Income 36551 23652 7812 12331 4062
Interest Income (Expense), Net Non-Operating -1824 560 -538 -877 -538
Gain (Loss) on Sale of Assets 0 99 -237 32 71
Net Income Before Taxes 34729 24311 7036 11485 3594
Net Income After Taxes 31401 22459 6666 10545 3264
Minority Interest -35 -45 -36 -29 -36
Net Income Before Extra. Items 31366 22414 6630 10516 3228
Total Extraordinary Items 6 -434 2529 5757 7924
Net Income 31372 21980 9159 16273 11152
Total Adjustments to Net Income -1 0 -1 0
Income Available to Common Excl. Extra. Items 31366 22413 6630 10515 3228
Income Available to Common Incl. Extra. Items 31372 21979 9159 16272 11152
Diluted Net Income 31372 21979 9159 16272 11152
Diluted Weighted Average Shares 5733 5708 5632 5675 5977
Diluted EPS Excluding Extraordinary Items 5.47113 3.92659 1.1772 1.85286 0.54007
Dividends per Share - Common Stock Primary Issue 1.6 1.56 1.52 1.44 1.36
Diluted Normalized EPS 5.36543 4.09303 1.45366 1.22837 1.04885
Other, Net 2 -1 -1 -1
Jul 2023 Mar 2023 Apr 2023 Dec 2022 Oct 2022
Total revenue 12734 18282 18282 24290 22638
Revenue 12734 18282 18282 24290 22638
Cost of Revenue, Total 3402 5025 5025 9821 6088
Gross Profit 9332 13257 13257 14469 16550
Total Operating Expense 10560 11495 11706 19124 13226
Selling/General/Admin. Expenses, Total 3574 3485 3485 4877 3542
Research & Development 2681 2526 2526 3688 3220
Depreciation / Amortization 1184 1103 1103 1131 822
Unusual Expense (Income) -57 121 121 643 288
Other Operating Expenses, Total -224 -765 -554 -1036 -734
Operating Income 2174 6787 6576 5166 9412
Interest Income (Expense), Net Non-Operating 99 -524 -313 57 -403
Gain (Loss) on Sale of Assets -5 7 7 6 -7
Other, Net 1 2 -1
Net Income Before Taxes 2269 6270 6270 5231 9001
Net Income After Taxes 2340 5555 5555 5001 8645
Minority Interest -11 -13 -13 -8 -15
Net Income Before Extra. Items 2329 5542 5542 4993 8630
Total Extraordinary Items -2 1 1 2 -21
Net Income 2327 5543 5543 4995 8609
Total Adjustments to Net Income -1 -1
Income Available to Common Excl. Extra. Items 2329 5542 5542 4992 8629
Income Available to Common Incl. Extra. Items 2327 5543 5543 4994 8608
Diluted Net Income 2327 5543 5543 4994 8608
Diluted Weighted Average Shares 5713 5727 5727 5745 5718
Diluted EPS Excluding Extraordinary Items 0.40767 0.9677 0.9677 0.86893 1.50909
Dividends per Share - Common Stock Primary Issue 0.41 0.41 0.41 0.4 0.4
Diluted Normalized EPS 0.33643 0.9113 0.9113 0.87955 1.54162
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 51259 59693 35067 32803 49926
Cash and Short Term Investments 22732 31069 12221 9646 18833
Cash & Equivalents 416 1944 1784 1121 1139
Short Term Investments 22316 29125 10437 8525 17694
Total Receivables, Net 14529 11479 7930 6772 8025
Accounts Receivable - Trade, Net 10952 11479 7930 6772 8025
Total Inventory 8981 9059 8046 7068 7508
Other Current Assets, Total 5017 8086 6870 9317 15560
Total Assets 197205 181476 154229 167594 159422
Property/Plant/Equipment, Total - Net 19276 17721 15293 14258 13385
Property/Plant/Equipment, Total - Gross 34450 32794 30104 29248 29977
Accumulated Depreciation, Total -15174 -15074 -14812 -14990 -16591
Goodwill, Net 51375 49208 49577 48202 53411
Intangibles, Net 43370 25146 28471 33936 35211
Long Term Investments 15069 21526 20262 20147 2767
Other Long Term Assets, Total 16856 8182 5559 18248 4722
Total Current Liabilities 42138 42671 25920 37304 31858
Accounts Payable 6809 5578 4309 3887 4674
Accrued Expenses 4027 3781 3379 2659 2397
Notes Payable/Short Term Debt 395 605 701 14733 4055
Current Port. of LT Debt/Capital Leases 2550 1636 2002 1462 4776
Other Current Liabilities, Total 28357 31071 15529 14563 15956
Total Liabilities 101545 104276 90991 104450 96015
Total Long Term Debt 32884 36195 37133 35955 32909
Long Term Debt 32884 36195 37133 35955 32909
Deferred Income Tax 1023 349 4063 5652 3700
Minority Interest 256 262 235 303 351
Other Liabilities, Total 25244 24799 23640 25236 27197
Total Equity 95660 77200 63238 63144 63407
Preferred Stock - Non Redeemable, Net 0 17 19
Common Stock 476 473 470 468 467
Additional Paid-In Capital 91802 90591 88674 87428 86253
Retained Earnings (Accumulated Deficit) 125656 103394 96770 97670 89554
Treasury Stock - Common -113969 -111361 -110988 -110801 -101610
Unrealized Gain (Loss) 220 -220 116 -35 -68
Other Equity, Total -8525 -5677 -11804 -11603 -11208
Total Liabilities & Shareholders’ Equity 197205 181476 154229 167594 159422
Total Common Shares Outstanding 5616 5620 5567 5534 5717
Total Preferred Shares Outstanding 0 0 0 0.00043 0.00048
Oct 2023 Jul 2023 Apr 2023 Mar 2023 Dec 2022
Total Current Assets 74012 73347 50078 51259
Cash and Short Term Investments 44181 44785 19972 22732
Cash & Equivalents 3148 2632 2166 416
Short Term Investments 41033 42153 17806 22316
Total Receivables, Net 15003 13425 15445 14529
Accounts Receivable - Trade, Net 11086 10231 12305 10952
Total Inventory 10204 10310 9541 8981
Other Current Assets, Total 4624 4827 5120 5017
Total Assets 215021 220168 195617 197205
Property/Plant/Equipment, Total - Net 17862 17488 17052 16274
Property/Plant/Equipment, Total - Gross 33641 33042 32566 31448
Accumulated Depreciation, Total -15779 -15554 -15514 -15174
Goodwill, Net 51527 51572 51476 51375
Intangibles, Net 40224 41406 42002 43370
Long Term Investments 14239 15066 14743 15069
Other Long Term Assets, Total 17157 21289 20266 19858
Total Current Liabilities 31136 34647 36562 42138
Accounts Payable 5338 6081 6123 6809
Accrued Expenses 2372 1972 2277 3407
Notes Payable/Short Term Debt 298 420 621 395
Current Port. of LT Debt/Capital Leases 2250 3565 3567 2550
Other Current Liabilities, Total 20878 22609 23974 28977
Total Liabilities 118087 121149 94647 101545
Total Long Term Debt 61048 61356 31704 32884
Long Term Debt 61048 61356 31704 32884
Deferred Income Tax 1125 1232 1067 1023
Minority Interest 270 274 266 256
Other Liabilities, Total 24508 23640 25048 25244
Total Equity 96934 99019 100970 95660
Common Stock 478 478 478 476
Additional Paid-In Capital 92496 92329 92153 91802
Retained Earnings (Accumulated Deficit) 126411 128796 131102 125656
Treasury Stock - Common -114485 -114482 -114473 -113969
Unrealized Gain (Loss) -140 -112 -149 220
Other Equity, Total -7826 -7990 -8141 -8525
Total Liabilities & Shareholders’ Equity 215021 220168 195617 197205
Total Common Shares Outstanding 5646 5645 5645 5616
Total Preferred Shares Outstanding 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 31407 22025 9652 16302 11188
Cash From Operating Activities 29267 32580 14403 12587 15827
Cash From Operating Activities 5064 5191 4777 6010 6384
Deferred Taxes -3764 -4293 -1468 614 -2205
Non-Cash Items 1016 -3147 1717 -6307 1387
Cash Taxes Paid 7867 7427 3153 3664 3655
Cash Interest Paid 1442 1467 1641 1587 1311
Changes in Working Capital -4456 12804 -275 -4032 -927
Cash From Investing Activities -15783 -22546 -4271 -3945 4525
Capital Expenditures -3236 -2711 -2791 -2594 -2196
Other Investing Cash Flow Items, Total -12547 -19835 -1480 -1351 6721
Cash From Financing Activities -14834 -9816 -9649 -8485 -20441
Financing Cash Flow Items -335 16 11121 -735 -589
Total Cash Dividends Paid -8983 -8729 -8440 -8043 -7978
Issuance (Retirement) of Stock, Net -2000 0 425 -8471 -10939
Issuance (Retirement) of Debt, Net -3516 -1103 -12755 8764 -935
Foreign Exchange Effects -165 -59 -8 -32 -116
Net Change in Cash -1515 159 475 125 -205
Mar 2023 Apr 2023 Dec 2022 Oct 2022 Jul 2022
Net income/Starting Line 5556 31407 26404 17781
Cash From Operating Activities 1212 29267 20685 14712
Cash From Operating Activities 1487 5064 3545 2362
Deferred Taxes -598 -3764 -3399 -3461
Non-Cash Items 273 1016 1740 1524
Cash Taxes Paid 329 7867 4919 3098
Cash Interest Paid 419 1442 1121 771
Changes in Working Capital -5506 -4456 -7605 -3494
Cash From Investing Activities 3315 -15783 -11373 -10746
Capital Expenditures -1139 -3236 -2235 -1394
Other Investing Cash Flow Items, Total 4454 -12547 -9138 -9352
Cash From Financing Activities -2771 -14834 -9819 -4058
Financing Cash Flow Items -436 -335 -342 -347
Total Cash Dividends Paid -2303 -8983 -6738 -4493
Issuance (Retirement) of Debt, Net -32 -3516 -739 2782
Foreign Exchange Effects -2 -165 -139 -67
Net Change in Cash 1754 -1515 -646 -159
Issuance (Retirement) of Stock, Net 0 -2000 -2000 -2000
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 8.9546 505575152 -131409 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.2889 298607279 2660151 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 5.0869 287201692 5374611 2023-06-30 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 4.1288 233110040 14178107 2023-06-30 LOW
Capital World Investors Investment Advisor 3.5249 199012806 -32499562 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.9992 112872506 3019727 2023-06-30 LOW
Charles Schwab Investment Management, Inc. Investment Advisor 1.5299 86378754 2477573 2023-06-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 1.089 61484622 4931781 2022-12-31 LOW
State Farm Insurance Companies Insurance Company 0.9654 54508560 247023 2023-06-30 LOW
MFS Investment Management Investment Advisor/Hedge Fund 0.9553 53935116 742147 2023-06-30 LOW
Morgan Stanley Smith Barney LLC Investment Advisor 0.8381 47316359 1762133 2023-06-30 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.8325 47002433 3357154 2023-06-30 LOW
Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.7765 43840720 2093282 2023-06-30 LOW
BofA Global Research (US) Research Firm 0.7156 40402328 -6565149 2023-06-30 LOW
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.7154 40388546 -2155011 2023-06-30 LOW
BlackRock Asset Management Ireland Limited Investment Advisor 0.6965 39326525 -781477 2023-06-30 LOW
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 0.538 30376252 -1099072 2023-06-30 LOW
Capital International Investors Investment Advisor 0.5073 28644679 -27358256 2023-06-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 0.443 25011923 -4421727 2023-06-30 LOW
Mellon Investments Corporation Investment Advisor/Hedge Fund 0.4362 24627529 -973999 2023-09-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Pfizer Company profile

Pfizer Inc. (PFE) is a New York-based multinational corporation engaged in the business of discovering, developing, producing and selling pharmaceuticals. It is one of the world's largest pharmaceutical companies and ranked 64 on the 2020 Fortune 500 list.

Pfizer shares are traded on the New York Stock Exchange under the ticker symbol PFE. The company is a constituent of the S&P 100 Index and S&P 500 Index (US500). Pfizer stock was also a constituent of the Dow Jones Industrial Average (US30) from 2004 to 2020. However, it was replaced by Amgen (AMGN) on August 31, 2020.

Get all the information you need on the PFE stock price today with Capital.com’s comprehensive chart.

The company was founded in 1849 in New York by two cousins, Charles Pfizer and Charles F Erhart. Already by 1906, Pfizer’s sales totalled $3.4m (£2.6m, €2.9m). Originally a manufacturer of fine chemicals, the business moved into pharmaceuticals in the second half of the 20th century.

Acquisitions have been one of the key growth strategies for Pfizer. Some of the firm’s major purchases include Warner-Lambert in 2000, Pharmacia in 2003, Wyeth in 2009, King Pharmaceuticals in 2010, Innopharma in 2014, and Medivation and Anacor Pharmaceuticals in 2016. In December 2018, the company announced a joint merger of its consumer healthcare division with the British pharma giant GlaxoSmithKline. The transaction closed in August 2019.

Today, Pfizer is headquartered in New York City, and its research HQ is in Groton, Connecticut. The company has research and development staff across the world to support its product pipeline. As well as numerous locations across the US, the company also has sites in Europe, India, Japan, Australia and Latin America.

Pfizer manufactures a broad range of medicines and vaccines for such therapeutic areas as immunology and inflammation, cardiovascular and metabolic diseases, oncology, neurological and psychiatric illnesses, and rare diseases. It is involved both in carrying out clinical trials and conducting research and development. Among its best-known products are the blockbuster drug Lipitor, the antibiotic Zithromax, and erectile dysfunction treatment Viagra.

In November 2020, Pfizer’s Covid-19 vaccine, developed with the German drugmaker BioNTech (BNTX), was found to be more than 90 per cent effective.

With Capital.com’s PFE chart you can not only quickly view the current Pfizer stock quote, but also trace the company’s shares value in historic terms.

In regard to the Pfizer Inc stock history, the company went public on June 22, 1942. The $5.9 million IPO was one of the largest of that year, with Pfizer offering shares at $24.75 apiece and reaching a market cap of $12.4 million on the first day of trading.

The business’ growth into one of the world's largest pharmaceutical corporations has generated hefty profits for its early investors. By 1998, when its famous Viagra medicine was launched in the US and Europe, Pfizer’s market cap had already soared by more than a million per cent from its IPO valuation.

The Pfizer Inc. share price had been on a general upward trend from the global financial crisis, when it fell as low as $12.30, up until November 2018, when it peaked at $46.30.

On March 23, 2020, the stock plunged to $27.88 per share amid the global economic uncertainty caused by the Covid-19 pandemic. The shares then quickly recovered to trade at $37-$39 throughout May, right before falling to $32 by the end of June. The Pfizer share value then inched higher to fluctuate in the $36-$39 range throughout August-October. The stock briefly broke out in early November after the company's Covid-19 vaccine, tested on 43,500 people, proved 90 per cent effective in a final-phase study.

You can go long or short on the company’s shares and trace all the latest ups and downs of the Pfizer stock price now using Capital.com’s proprietary trading platform.

Industry: Pharmaceuticals (NEC)

66 Hudson Boulevard East
NEW YORK
NEW YORK 10001-2192
US

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

US100

17,914.30 Price
-0.300% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 22:00 (UTC)
Spread 7.0

Gold

2,035.76 Price
+0.560% 1D Chg, %
Long position overnight fee -0.0185%
Short position overnight fee 0.0103%
Overnight fee time 22:00 (UTC)
Spread 0.50

BTC/USD

51,664.65 Price
+1.170% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Oil - Crude

76.56 Price
-2.240% 1D Chg, %
Long position overnight fee 0.0163%
Short position overnight fee -0.0382%
Overnight fee time 22:00 (UTC)
Spread 0.030
video

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading